1,191 results on '"Rai, Kanti R."'
Search Results
102. Determining the Clinical Course and Outcome in Chronic Lymphocytic Leukemia
103. Pulmonary complications in chronic lymphocytic leukemia
104. Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011
105. Campath-1H for Chronic Lymphocytic Leukemia
106. Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011
107. Fludarabine for Chronic Lymphocytic Leukemia
108. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone
109. Interferon in the treatment of hairy-cell leukemia
110. Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia
111. CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib
112. Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?
113. Molecular Analysis of FcγRIIb-BCR Colligation Signaling in Primary CLL Lymphocytes
114. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia
115. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes: Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA.
116. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
117. Fludarabine for chronic lymphocytic leukemia
118. Where do we go from here?
119. Chronic Lymphocytic Leukemia: New Insights into Biology and Therapy
120. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options
121. CLL Intraclonal Fractions Defined By Time Since Cell Birth/Division Promote a Leukemia-Supportive, Immune-Tolerant Microenvironment By Distinct Mechanisms
122. Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue
123. Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl
124. Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model
125. Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia
126. Chronic Lymphocytic Leukemia B Cells Display IgM and IgD Isotype-Restricted Features That Affect Association with Co-Receptors, BCR Signaling, and Leukemic B-Cell Growth In Vivo
127. Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia
128. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase
129. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission
130. Chylothorax in Patients With Chronic Lymphocytic Leukemia: A Case Series
131. Abstract 960: Mechanisms underlying primary ibrutinib sensitivity in CLL
132. APOBEC gene family expression and hallmarks in chronic lymphocytic leukemia
133. Introduction
134. Chronic Lymphocytic Leukemia
135. Comparative Density Analyses of B Cell Receptor-Complex Components (Membrane IgM, Membrane IgD, and Stimulatory/Inhibitory Co-Receptors) on Intraclonal Subpopulations of CLL B Cells, before and during Ibrutinib Therapy
136. A Distributed International Patient Data Registry for Hairy Cell Leukemia
137. The RNA-Binding Protein Musashi 2 Is Upregulated in the Proliferative Fraction of CLL Clones, Particularly in U-CLL Patients, and Its Silencing Induces Programmed Cell Death
138. Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia
139. In CLL, Myeloid-Derived Suppressor Cells and Their Monocytic and Granulocytic Varieties Differ in T-Cell Subset Association and Polarization Induction
140. In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment
141. Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
142. Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status
143. Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6–deficient process
144. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
145. The Correlation of APOBEC Gene Family Member Expression with Worse CLL Patient Outcome Suggests a Role in CLL Mutational Evolution
146. Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells
147. Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia
148. The RNA Binding Protein Musashi 2 Is up-Regulated in the Proliferative B-Cell Fraction of Chronic Lymphocytic Leukemia Clones
149. Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation
150. Characterization of Atrial Fibrillation and Bleeding Risk Factors in Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Retrospective Cohort Study of Administrative Medical Claims Data in the United States (US)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.